Investigation of the relationship between chronic montelukast treatment, asthma and depression-like behavior in mice.
asthma
depression
forced swim test
montelukast
neuropsychiatric side-effects
ovalbumin
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
10
01
2020
accepted:
26
06
2020
entrez:
2
12
2020
pubmed:
3
12
2020
medline:
3
12
2020
Statut:
ppublish
Résumé
In 2008, the Food and Drug Administration of the US issued a warning about the neuropsychiatric side effects of montelukast. Previous clinical studies on montelukast have reported conflicting results and, to the best of our knowledge, no experimental studies concerning these side effects had been conducted. In the current study, the effect of montelukast on depression-like behavior in an ovalbumin (OVA)-induced mouse model was investigated. A total of 3 OVA challenges were applied at 2 week intervals for the persistence of asthma. Depression-like behavior was assessed using forced swim tests following each challenge and locomotor activities were evaluated using open field tests. At the end of the current study, plasma montelukast concentrations were measured and the development of asthma and effect of montelukast treatment were histopathologically examined. Inflammation scores that were increased in the OVA mice following all challenges were indicated to be reduced by montelukast treatment. The immobility time of mice increased beginning with the first challenge and this was also reduced by montelukast treatment. Montelukast administration to the control mice did not alter immobility times. Moreover, motor activity of the OVA and montelukast-treated mice were not altered. The results indicated there was no association between chronic montelukast treatment and depression. Furthermore, the chronic administration of montelukast to non-asthmatic mice did not increase immobility. However, depressive behavior increased at all time points in the OVA mice. These results indicated that chronic montelukast treatment is not associated with depression-like behavior and confirmed the association between asthma and depression. Further studies are required to provide an improved understanding of the neuropsychiatric side effects of montelukast.
Identifiants
pubmed: 33262813
doi: 10.3892/etm.2020.9459
pii: ETM-0-0-09459
pmc: PMC7690246
doi:
Types de publication
Journal Article
Langues
eng
Pagination
27Informations de copyright
Copyright: © Tel et al.
Références
Am J Public Health. 2005 Apr;95(4):717-22
pubmed: 15798135
ILAR J. 2014;55(2):297-309
pubmed: 25225308
Pulm Pharmacol Ther. 1999;12(2):107-10
pubmed: 10373391
Pharmacology. 2014;94(1-2):60-70
pubmed: 25196099
Drug Saf. 2016 Jan;39(1):69-78
pubmed: 26620206
Trends Pharmacol Sci. 2010 Jul;31(7):335-43
pubmed: 20554041
J Allergy Clin Immunol. 2009 Oct;124(4):699-706.e8
pubmed: 19815116
Curr Treat Options Neurol. 2008 Sep;10(5):363-76
pubmed: 18782509
Nat Protoc. 2012 May 03;7(6):1009-14
pubmed: 22555240
Am J Respir Crit Care Med. 2014 May 1;189(9):1044-51
pubmed: 24456492
Arch Dis Child. 2016 Oct;101(10):968-70
pubmed: 27091848
Am J Epidemiol. 1999 Nov 15;150(10):1107-16
pubmed: 10568627
Ann Allergy Asthma Immunol. 2014 May;112(5):432-6
pubmed: 24650441
Genes Brain Behav. 2008 Jul;7(5):532-42
pubmed: 18221379
Psychosom Med. 2009 Feb;71(2):187-95
pubmed: 19073754
Eur Respir J. 2017 Aug 17;50(2):
pubmed: 28818882
J Allergy Clin Immunol. 2008 Oct;122(4):828-829
pubmed: 18760460
Expert Opin Drug Saf. 2009 May;8(3):273-82
pubmed: 19505261
Psychopharmacology (Berl). 2005 Jan;177(3):245-55
pubmed: 15609067
J Psychosom Res. 1999 Mar;46(3):283-9
pubmed: 10193919
Nature. 1999 Jun 24;399(6738):789-93
pubmed: 10391245
Pharmacol Res Perspect. 2017 Oct;5(5):
pubmed: 28971612
Open Neuropsychopharmacol J. 2008 Jan 1;1:1-5
pubmed: 19890443
Cochrane Database Syst Rev. 2019 Jan 28;1:CD011651
pubmed: 30687940
Proc Natl Acad Sci U S A. 2014 May 13;111(19):7138-43
pubmed: 24782539
Sci Rep. 2018 May 2;8(1):6925
pubmed: 29720689
J Allergy Clin Immunol. 2009 Oct;124(4):691-6.e6
pubmed: 19815114
Int J Child Health Hum Dev. 2008;1(3):313-322
pubmed: 19430577
J Asthma Allergy. 2017 Nov 07;10:293-301
pubmed: 29158683
J Adolesc Health. 2007 Nov;41(5):455-63
pubmed: 17950165
Nature. 1977 Apr 21;266(5604):730-2
pubmed: 559941
Biopharm Drug Dispos. 1997 Dec;18(9):769-77
pubmed: 9429741
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):74-5
pubmed: 26772927
Curr Opin Pulm Med. 2011 Jan;17(1):39-44
pubmed: 20975562
Case Rep Pulmonol. 2013;2013:813786
pubmed: 24093069
Arch Int Pharmacodyn Ther. 1977 Oct;229(2):327-36
pubmed: 596982
Int Arch Allergy Immunol. 2010;153(3):249-58
pubmed: 20484923
J Affect Disord. 2014 Sep;166:22-9
pubmed: 25012406
J Allergy Clin Immunol. 2012 Aug;130(2):368-75
pubmed: 22698520
J Asthma. 2011 Apr;48(3):253-8
pubmed: 21341970
Allergy. 2010 Oct;65(10):1298-305
pubmed: 20456315
Chest. 2010 Mar;137(3):609-16
pubmed: 19837824
Neurosci Biobehav Rev. 2018 Jan;84:1-11
pubmed: 29128579
Thorax. 2014 Nov;69 Suppl 1:1-192
pubmed: 25323740
Pharmacoepidemiol Drug Saf. 2015 Apr;24(4):435-45
pubmed: 25683909
Biomed Environ Sci. 2014 Apr;27(4):268-80
pubmed: 24758755
J Investig Allergol Clin Immunol. 2012;22(6):452-3
pubmed: 23101197
Exp Gerontol. 2014 Sep;57:149-54
pubmed: 24862634
PLoS One. 2015 Jul 21;10(7):e0132424
pubmed: 26197472
J Pharm Bioallied Sci. 2014 Apr;6(2):97-103
pubmed: 24741277
Curr Opin Allergy Clin Immunol. 2012 Feb;12(1):39-41
pubmed: 22157151
Pulm Med. 2013;2013:929028
pubmed: 23577252